期刊
CLINICAL GENITOURINARY CANCER
卷 17, 期 5, 页码 319-331出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2019.06.002
关键词
Meta-analysis; Metastatic renal cell cancer; Schedule 2/1; Schedule 4/2; Sunitinib
资金
- Natural Science Foundation of China [8177103120]
The treatment of renal cell carcinoma has achieved certain curative effects with the innovation of clinical drugs, such as sunitinib. However, the clinical efficacy and complication rate of the sunitinib 2/1 and 4/2 schedule in metastatic renal cell cancer remain unclear. In this study we aimed to resolve this issue by using meta-analysis to provide more theoretical guidance for clinical use. Several outcome measurements were included in this study to compare the 2 schedules such as complete response, partial response, stable disease, progressive disease, progression-free survival, overall survival, and complications. In the contrast analysis, the sunitinib 2/1 and 4/2 schedule resulted in significant improvements in prognosis. However, the sunitinib 2/1 schedule was superior to the 4/2 schedule in terms of controlling stable disease and causing fewer complications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据